Autolus Therapeutics (NASDAQ:AUTL) Given New $6.00 Price Target at Wells Fargo & Company

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) had its price objective decreased by equities researchers at Wells Fargo & Company from $8.00 to $6.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Wells Fargo & Company's price objective points to a potential upside of 262.54% from the stock's previous close.

Separately, Needham & Company LLC reiterated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $9.52.

Autolus Therapeutics Stock Down 3.2 %

AUTL traded down $0.06 during trading on Friday, reaching $1.66. 247,485 shares of the stock traded hands, compared to its average volume of 1,380,174. The stock's 50-day moving average is $2.01 and its 200 day moving average is $2.88. Autolus Therapeutics has a 12 month low of $1.56 and a 12 month high of $6.60. The stock has a market capitalization of $440.39 million, a PE ratio of -1.37 and a beta of 2.07.

Remove Ads

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.12. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $2.98 million. As a group, equities research analysts anticipate that Autolus Therapeutics will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in AUTL. FMR LLC lifted its holdings in shares of Autolus Therapeutics by 44.6% in the third quarter. FMR LLC now owns 17,773,873 shares of the company's stock valued at $64,519,000 after purchasing an additional 5,478,706 shares in the last quarter. Capstone Investment Advisors LLC bought a new position in Autolus Therapeutics during the 3rd quarter valued at $51,000. Bellevue Group AG boosted its holdings in Autolus Therapeutics by 27.7% during the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company's stock worth $151,000 after acquiring an additional 9,000 shares during the last quarter. Erste Asset Management GmbH bought a new stake in shares of Autolus Therapeutics in the 3rd quarter worth $708,000. Finally, HighVista Strategies LLC raised its holdings in shares of Autolus Therapeutics by 2.7% in the third quarter. HighVista Strategies LLC now owns 533,024 shares of the company's stock valued at $1,935,000 after purchasing an additional 14,204 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.